Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Conditions: Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma Interventions: Drug: Zongertinib; Drug: Trastuzumab deruxtecan; Drug: Trastuzumab emtansine Sponsors: Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Breast Cancer | Cancer | Cancer & Oncology | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Research | Study